<DOC>
	<DOC>NCT01969214</DOC>
	<brief_summary>Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several studies demonstrating their efficacy, the investigators are conducting this study to look into the efficacy and safety of IQP-MM-101 in diarrhoea control.</brief_summary>
	<brief_title>Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Age 18 to 65 years Good general health Acute diarrhoea episode defined as at least three watery stools per 24 hours over a period of 48 hours or less Acute diarrhoea of presumed infectious origin Patients with usually normal bowel movements (defecations) before onset of diarrhoea, that is, at least three normal stools per week and three or less normal stools per day Negative pregnancy test (ß HCGtest) for women with child bearing potential Written informed consent is a prerequisite for subject enrollment Known sensitivity to the ingredients of the device Fever &gt;38,5◦C Blood or pus in stools Dehydration requiring intravenous rehydration History of chronic diarrhoea (three or more loose or watery stools per day for at least 12 weeks, consecutive or not, in the preceding 12 months) Use of antidiarrhoeal agents over the month prior to baseline Diarrhoea possibly induced by antibiotics, laxative agents, thyroid hormones, or colchicine Irritable bowel syndrome Any other acute or chronic disease that could interfere with the evaluation of study device Females who are pregnant or lactating Subjects who have participated in another clinical trial in the 30 days before treatment period Inability to comply Presence of other factor(s) that, in the investigator's judgement, should preclude subject participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>